APO Research
Talk to an analyst

APO RESEARCH · REPORT

Giant Cell Arteritis Therapeutic

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Giant Cell Arteritis Therapeutic Market Outlook and Growth Opportunities 2026

22 December 2025195 pages

Choose your research edition.

Industry ResearchGiant Cell Arteritis Therapeutic Industry Research Report 2026134 pages · $2,950 USDIndustry Growth & TrendsGlobal Giant Cell Arteritis Therapeutic Industry Growth and Trends Forecast to 2032111 pages · $3,450 USDMarket StructureGlobal Giant Cell Arteritis Therapeutic Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Giant Cell Arteritis Therapeutic Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Giant Cell Arteritis Therapeutic Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Giant Cell Arteritis Therapeutic market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Giant Cell Arteritis Therapeutic is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Giant Cell Arteritis Therapeutic is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Giant Cell Arteritis Therapeutic is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Giant Cell Arteritis Therapeutic market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Giant Cell Arteritis Therapeutic market include Abbott, Sanofi, Johnson & Johnson Services, Inc., Novartis AG, GlaxoSmithKline plc, AbbVie, Inc., Regeneron, Lahey Clinic Foundation and Kiniksa Pharmaceuticals, Ltd., among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Giant Cell Arteritis Therapeutic market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Giant Cell Arteritis Therapeutic and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Giant Cell Arteritis Therapeutic revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Giant Cell Arteritis Therapeutic market.

Giant Cell Arteritis Therapeutic Segment by Company

Abbott

Sanofi

Johnson & Johnson Services, Inc.

Novartis AG

GlaxoSmithKline plc

AbbVie, Inc.

Regeneron

Lahey Clinic Foundation

Kiniksa Pharmaceuticals, Ltd.

Johns Hopkins Hospital

Fortis Healthcare

F. Hoffmann-La Roche Ltd.

Duke University Health System

Bristol-Myers Squibb Company

American College of Rheumatology

Giant Cell Arteritis Therapeutic Segment by Type

Tocilizumab

Prednisone

Methotrexate

Aspirin

Giant Cell Arteritis Therapeutic Segment by Application

Anticoagulants

Immunosuppressive Agents

Corticosteroids

Others

Giant Cell Arteritis Therapeutic Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Giant Cell Arteritis Therapeutic status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Giant Cell Arteritis Therapeutic key companies, revenue, market share, and recent developments.

3. To split the Giant Cell Arteritis Therapeutic breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Giant Cell Arteritis Therapeutic market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Giant Cell Arteritis Therapeutic significant trends, drivers, influence factors in global and regions.

6. To analyze Giant Cell Arteritis Therapeutic competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Giant Cell Arteritis Therapeutic market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Giant Cell Arteritis Therapeutic and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Giant Cell Arteritis Therapeutic.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Giant Cell Arteritis Therapeutic industry.

Chapter 3: Detailed analysis of Giant Cell Arteritis Therapeutic company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Giant Cell Arteritis Therapeutic in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Giant Cell Arteritis Therapeutic in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Giant Cell Arteritis Therapeutic Industry Trends Table 2. Giant Cell Arteritis Therapeutic Industry Drivers Table 3. Giant Cell Arteritis Therapeutic Industry Opportunities and Challenges Table 4. Giant Cell Arteritis Therapeutic Industry Restraints Table 5. Global Giant Cell Arteritis Therapeutic Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Giant Cell Arteritis Therapeutic Revenue Share by Company (2021-2026) Table 7. Global Giant Cell Arteritis Therapeutic Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Giant Cell Arteritis Therapeutic Key Company Manufacturing Base & Headquarters Table 9. Global Giant Cell Arteritis Therapeutic Company, Product Type & Application Table 10. Global Giant Cell Arteritis Therapeutic Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Giant Cell Arteritis Therapeutic by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Tocilizumab Table 15. Significant Companies of Prednisone Table 16. Significant Companies of Methotrexate Table 17. Significant Companies of Aspirin Table 18. Global Giant Cell Arteritis Therapeutic Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Giant Cell Arteritis Therapeutic Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Giant Cell Arteritis Therapeutic Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Giant Cell Arteritis Therapeutic Sales Value Share by Type (2021-2026) Table 22. Global Giant Cell Arteritis Therapeutic Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Anticoagulants Table 24. Significant Companies of Immunosuppressive Agents Table 25. Significant Companies of Corticosteroids Table 26. Significant Companies of Others Table 27. Global Giant Cell Arteritis Therapeutic Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Giant Cell Arteritis Therapeutic Sales Value by Application (2021-2026) & (US$ Million) Table 29. Global Giant Cell Arteritis Therapeutic Sales Value by Application (2027-2032) & (US$ Million) Table 30. Global Giant Cell Arteritis Therapeutic Sales Value Share by Application (2021-2026) Table 31. Global Giant Cell Arteritis Therapeutic Sales Value Share by Application (2027-2032) Table 32. Global Giant Cell Arteritis Therapeutic Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Giant Cell Arteritis Therapeutic Sales Value by Region (2021-2026) & (US$ Million) Table 34. Global Giant Cell Arteritis Therapeutic Sales Value Share by Region (2021-2026) Table 35. Global Giant Cell Arteritis Therapeutic Sales Value by Region (2027-2032) & (US$ Million) Table 36. Global Giant Cell Arteritis Therapeutic Sales Value Share by Region (2027-2032) Table 37. Global Giant Cell Arteritis Therapeutic Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Giant Cell Arteritis Therapeutic Sales Value by Country (2021-2026) & (US$ Million) Table 39. Global Giant Cell Arteritis Therapeutic Sales Value Market Share by Country (2021-2026) Table 40. Global Giant Cell Arteritis Therapeutic Sales Value by Country (2027-2032) & (US$ Million) Table 41. Global Giant Cell Arteritis Therapeutic Sales Value Market Share by Country (2027-2032) Table 42. Abbott Company Information Table 43. Abbott Business Overview Table 44. Abbott Giant Cell Arteritis Therapeutic Revenue (US$ Million) and Gross Margin (2021-2026) Table 45. Abbott Giant Cell Arteritis Therapeutic Product Portfolio Table 46. Abbott Recent Development Table 47. Sanofi Company Information Table 48. Sanofi Business Overview Table 49. Sanofi Giant Cell Arteritis Therapeutic Revenue (US$ Million) and Gross Margin (2021-2026) Table 50. Sanofi Giant Cell Arteritis Therapeutic Product Portfolio Table 51. Sanofi Recent Development Table 52. Johnson & Johnson Services, Inc. Company Information Table 53. Johnson & Johnson Services, Inc. Business Overview Table 54. Johnson & Johnson Services, Inc. Giant Cell Arteritis Therapeutic Revenue (US$ Million) and Gross Margin (2021-2026) Table 55. Johnson & Johnson Services, Inc. Giant Cell Arteritis Therapeutic Product Portfolio Table 56. Johnson & Johnson Services, Inc. Recent Development Table 57. Novartis AG Company Information Table 58. Novartis AG Business Overview Table 59. Novartis AG Giant Cell Arteritis Therapeutic Revenue (US$ Million) and Gross Margin (2021-2026) Table 60. Novartis AG Giant Cell Arteritis Therapeutic Product Portfolio Table 61. Novartis AG Recent Development Table 62. GlaxoSmithKline plc Company Information Table 63. GlaxoSmithKline plc Business Overview Table 64. GlaxoSmithKline plc Giant Cell Arteritis Therapeutic Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. GlaxoSmithKline plc Giant Cell Arteritis Therapeutic Product Portfolio Table 66. GlaxoSmithKline plc Recent Development Table 67. AbbVie, Inc. Company Information Table 68. AbbVie, Inc. Business Overview Table 69. AbbVie, Inc. Giant Cell Arteritis Therapeutic Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. AbbVie, Inc. Giant Cell Arteritis Therapeutic Product Portfolio Table 71. AbbVie, Inc. Recent Development Table 72. Regeneron Company Information Table 73. Regeneron Business Overview Table 74. Regeneron Giant Cell Arteritis Therapeutic Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Regeneron Giant Cell Arteritis Therapeutic Product Portfolio Table 76. Regeneron Recent Development Table 77. Lahey Clinic Foundation Company Information Table 78. Lahey Clinic Foundation Business Overview Table 79. Lahey Clinic Foundation Giant Cell Arteritis Therapeutic Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Lahey Clinic Foundation Giant Cell Arteritis Therapeutic Product Portfolio Table 81. Lahey Clinic Foundation Recent Development Table 82. Kiniksa Pharmaceuticals, Ltd. Company Information Table 83. Kiniksa Pharmaceuticals, Ltd. Business Overview Table 84. Kiniksa Pharmaceuticals, Ltd. Giant Cell Arteritis Therapeutic Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Kiniksa Pharmaceuticals, Ltd. Giant Cell Arteritis Therapeutic Product Portfolio Table 86. Kiniksa Pharmaceuticals, Ltd. Recent Development Table 87. Johns Hopkins Hospital Company Information Table 88. Johns Hopkins Hospital Business Overview Table 89. Johns Hopkins Hospital Giant Cell Arteritis Therapeutic Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Johns Hopkins Hospital Giant Cell Arteritis Therapeutic Product Portfolio Table 91. Johns Hopkins Hospital Recent Development Table 92. Fortis Healthcare Company Information Table 93. Fortis Healthcare Business Overview Table 94. Fortis Healthcare Giant Cell Arteritis Therapeutic Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 95. Fortis Healthcare Giant Cell Arteritis Therapeutic Product Portfolio Table 96. Fortis Healthcare Recent Development Table 97. F. Hoffmann-La Roche Ltd. Company Information Table 98. F. Hoffmann-La Roche Ltd. Business Overview Table 99. F. Hoffmann-La Roche Ltd. Giant Cell Arteritis Therapeutic Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 100. F. Hoffmann-La Roche Ltd. Giant Cell Arteritis Therapeutic Product Portfolio Table 101. F. Hoffmann-La Roche Ltd. Recent Development Table 102. Duke University Health System Company Information Table 103. Duke University Health System Business Overview Table 104. Duke University Health System Giant Cell Arteritis Therapeutic Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 105. Duke University Health System Giant Cell Arteritis Therapeutic Product Portfolio Table 106. Duke University Health System Recent Development Table 107. Bristol-Myers Squibb Company Company Information Table 108. Bristol-Myers Squibb Company Business Overview Table 109. Bristol-Myers Squibb Company Giant Cell Arteritis Therapeutic Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 110. Bristol-Myers Squibb Company Giant Cell Arteritis Therapeutic Product Portfolio Table 111. Bristol-Myers Squibb Company Recent Development Table 112. American College of Rheumatology Company Information Table 113. American College of Rheumatology Business Overview Table 114. American College of Rheumatology Giant Cell Arteritis Therapeutic Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 115. American College of Rheumatology Giant Cell Arteritis Therapeutic Product Portfolio Table 116. American College of Rheumatology Recent Development Table 117. Research Programs/Design for This Report Table 118. Authors List of This Report Table 119. Secondary Sources Table 120. Primary Sources List of Figures Figure 1. Giant Cell Arteritis Therapeutic Product Image Figure 2. Global Giant Cell Arteritis Therapeutic Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Giant Cell Arteritis Therapeutic Market Size (2021-2032) & (US$ Million) Figure 4. Global Giant Cell Arteritis Therapeutic Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Tocilizumab Image Figure 8. Prednisone Image Figure 9. Methotrexate Image Figure 10. Aspirin Image Figure 11. Global Giant Cell Arteritis Therapeutic Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Giant Cell Arteritis Therapeutic Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Giant Cell Arteritis Therapeutic Sales Value Share by Type (2021-2032) Figure 14. Anticoagulants Image Figure 15. Immunosuppressive Agents Image Figure 16. Corticosteroids Image Figure 17. Others Image Figure 18. Global Giant Cell Arteritis Therapeutic Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Giant Cell Arteritis Therapeutic Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Giant Cell Arteritis Therapeutic Sales Value Share by Application (2021-2032) Figure 21. Global Giant Cell Arteritis Therapeutic Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 22. Global Giant Cell Arteritis Therapeutic Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 23. North America Giant Cell Arteritis Therapeutic Sales Value (2021-2032) & (US$ Million) Figure 24. North America Giant Cell Arteritis Therapeutic Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Europe Giant Cell Arteritis Therapeutic Sales Value (2021-2032) & (US$ Million) Figure 26. Europe Giant Cell Arteritis Therapeutic Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Asia-Pacific Giant Cell Arteritis Therapeutic Sales Value (2021-2032) & (US$ Million) Figure 28. Asia-Pacific Giant Cell Arteritis Therapeutic Sales Value Share by Country (%), 2025 VS 2032 Figure 29. South America Giant Cell Arteritis Therapeutic Sales Value (2021-2032) & (US$ Million) Figure 30. South America Giant Cell Arteritis Therapeutic Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Middle East & Africa Giant Cell Arteritis Therapeutic Sales Value (2021-2032) & (US$ Million) Figure 32. Middle East & Africa Giant Cell Arteritis Therapeutic Sales Value Share by Country (%), 2025 VS 2032 Figure 33. USA Giant Cell Arteritis Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. USA Giant Cell Arteritis Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. USA Giant Cell Arteritis Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Canada Giant Cell Arteritis Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Canada Giant Cell Arteritis Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Canada Giant Cell Arteritis Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Mexico Giant Cell Arteritis Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Mexico Giant Cell Arteritis Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Mexico Giant Cell Arteritis Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Germany Giant Cell Arteritis Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Germany Giant Cell Arteritis Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Germany Giant Cell Arteritis Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. France Giant Cell Arteritis Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. France Giant Cell Arteritis Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. France Giant Cell Arteritis Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. U.K. Giant Cell Arteritis Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. U.K. Giant Cell Arteritis Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. U.K. Giant Cell Arteritis Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Italy Giant Cell Arteritis Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Italy Giant Cell Arteritis Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Italy Giant Cell Arteritis Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Spain Giant Cell Arteritis Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Spain Giant Cell Arteritis Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Spain Giant Cell Arteritis Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Russia Giant Cell Arteritis Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Russia Giant Cell Arteritis Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Russia Giant Cell Arteritis Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Netherlands Giant Cell Arteritis Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Netherlands Giant Cell Arteritis Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Netherlands Giant Cell Arteritis Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Nordic Countries Giant Cell Arteritis Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Nordic Countries Giant Cell Arteritis Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Nordic Countries Giant Cell Arteritis Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. China Giant Cell Arteritis Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. China Giant Cell Arteritis Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. China Giant Cell Arteritis Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Japan Giant Cell Arteritis Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Japan Giant Cell Arteritis Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Japan Giant Cell Arteritis Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. South Korea Giant Cell Arteritis Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. South Korea Giant Cell Arteritis Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. South Korea Giant Cell Arteritis Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. India Giant Cell Arteritis Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. India Giant Cell Arteritis Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. India Giant Cell Arteritis Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Australia Giant Cell Arteritis Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Australia Giant Cell Arteritis Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Australia Giant Cell Arteritis Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Southeast Asia Giant Cell Arteritis Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Southeast Asia Giant Cell Arteritis Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Southeast Asia Giant Cell Arteritis Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Brazil Giant Cell Arteritis Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Brazil Giant Cell Arteritis Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Brazil Giant Cell Arteritis Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Argentina Giant Cell Arteritis Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Argentina Giant Cell Arteritis Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Argentina Giant Cell Arteritis Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Chile Giant Cell Arteritis Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Chile Giant Cell Arteritis Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Chile Giant Cell Arteritis Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Colombia Giant Cell Arteritis Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Colombia Giant Cell Arteritis Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Colombia Giant Cell Arteritis Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Peru Giant Cell Arteritis Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Peru Giant Cell Arteritis Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Peru Giant Cell Arteritis Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Giant Cell Arteritis Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Saudi Arabia Giant Cell Arteritis Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Giant Cell Arteritis Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Israel Giant Cell Arteritis Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Israel Giant Cell Arteritis Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Israel Giant Cell Arteritis Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. UAE Giant Cell Arteritis Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. UAE Giant Cell Arteritis Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. UAE Giant Cell Arteritis Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Turkey Giant Cell Arteritis Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Turkey Giant Cell Arteritis Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Turkey Giant Cell Arteritis Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Iran Giant Cell Arteritis Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Iran Giant Cell Arteritis Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Iran Giant Cell Arteritis Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Egypt Giant Cell Arteritis Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Egypt Giant Cell Arteritis Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Egypt Giant Cell Arteritis Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Years Considered Figure 118. Research Process Figure 119. Key Executives Interviewed

Scope & coverage.

Types
  • Tocilizumab
  • Prednisone
  • Methotrexate
  • Aspirin
Applications
  • Anticoagulants
  • Immunosuppressive Agents
  • Corticosteroids
  • Others
Companies covered
  • Abbott
  • Sanofi
  • Johnson & Johnson Services, Inc.
  • Novartis AG
  • GlaxoSmithKline plc
  • AbbVie, Inc.
  • Regeneron
  • Lahey Clinic Foundation
  • Kiniksa Pharmaceuticals, Ltd.
  • Johns Hopkins Hospital
  • Fortis Healthcare
  • F. Hoffmann-La Roche Ltd.
  • Duke University Health System
  • Bristol-Myers Squibb Company
  • American College of Rheumatology

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Giant Cell Arteritis Therapeutic Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Giant Cell Arteritis Therapeutic Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Giant Cell Arteritis Therapeutic Market Dynamics
  1. 2.1 Giant Cell Arteritis Therapeutic Industry Trends
  2. 2.2 Giant Cell Arteritis Therapeutic Industry Drivers
  3. 2.3 Giant Cell Arteritis Therapeutic Industry Opportunities and Challenges
  4. 2.4 Giant Cell Arteritis Therapeutic Industry Restraints
3 Giant Cell Arteritis Therapeutic Market by Company
  1. 3.1 Global Giant Cell Arteritis Therapeutic Company Revenue Ranking in 2025
  2. 3.2 Global Giant Cell Arteritis Therapeutic Revenue by Company (2021-2026)
  3. 3.3 Global Giant Cell Arteritis Therapeutic Company Ranking (2024-2026)
  4. 3.4 Global Giant Cell Arteritis Therapeutic Company Manufacturing Base and Headquarters
  5. 3.5 Global Giant Cell Arteritis Therapeutic Company Product Type and Application
  6. 3.6 Global Giant Cell Arteritis Therapeutic Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Giant Cell Arteritis Therapeutic Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Giant Cell Arteritis Therapeutic Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Giant Cell Arteritis Therapeutic Market by Type
  1. 4.1 Giant Cell Arteritis Therapeutic Type Introduction
  2. 4.1.1 Tocilizumab
  3. 4.1.2 Prednisone
  4. 4.1.3 Methotrexate
  5. 4.1.4 Aspirin
  6. 4.2 Global Giant Cell Arteritis Therapeutic Sales Value by Type
  7. 4.2.1 Global Giant Cell Arteritis Therapeutic Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Giant Cell Arteritis Therapeutic Sales Value by Type (2021-2032)
  9. 4.2.3 Global Giant Cell Arteritis Therapeutic Sales Value Share by Type (2021-2032)
5 Giant Cell Arteritis Therapeutic Market by Application
  1. 5.1 Giant Cell Arteritis Therapeutic Application Introduction
  2. 5.1.1 Anticoagulants
  3. 5.1.2 Immunosuppressive Agents
  4. 5.1.3 Corticosteroids
  5. 5.1.4 Others
  6. 5.2 Global Giant Cell Arteritis Therapeutic Sales Value by Application
  7. 5.2.1 Global Giant Cell Arteritis Therapeutic Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Giant Cell Arteritis Therapeutic Sales Value by Application (2021-2032)
  9. 5.2.3 Global Giant Cell Arteritis Therapeutic Sales Value Share by Application (2021-2032)
6 Giant Cell Arteritis Therapeutic Regional Value Analysis
  1. 6.1 Global Giant Cell Arteritis Therapeutic Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Giant Cell Arteritis Therapeutic Sales Value by Region (2021-2032)
  3. 6.2.1 Global Giant Cell Arteritis Therapeutic Sales Value by Region: 2021-2026
  4. 6.2.2 Global Giant Cell Arteritis Therapeutic Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Giant Cell Arteritis Therapeutic Sales Value (2021-2032)
  7. 6.3.2 North America Giant Cell Arteritis Therapeutic Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Giant Cell Arteritis Therapeutic Sales Value (2021-2032)
  10. 6.4.2 Europe Giant Cell Arteritis Therapeutic Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Giant Cell Arteritis Therapeutic Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Giant Cell Arteritis Therapeutic Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Giant Cell Arteritis Therapeutic Sales Value (2021-2032)
  16. 6.6.2 South America Giant Cell Arteritis Therapeutic Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Giant Cell Arteritis Therapeutic Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Giant Cell Arteritis Therapeutic Sales Value Share by Country, 2025 VS 2032
7 Giant Cell Arteritis Therapeutic Country-level Value Analysis
  1. 7.1 Global Giant Cell Arteritis Therapeutic Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Giant Cell Arteritis Therapeutic Sales Value by Country (2021-2032)
  3. 7.2.1 Global Giant Cell Arteritis Therapeutic Sales Value by Country (2021-2026)
  4. 7.2.2 Global Giant Cell Arteritis Therapeutic Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Giant Cell Arteritis Therapeutic Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Giant Cell Arteritis Therapeutic Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Giant Cell Arteritis Therapeutic Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Giant Cell Arteritis Therapeutic Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Giant Cell Arteritis Therapeutic Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Giant Cell Arteritis Therapeutic Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Giant Cell Arteritis Therapeutic Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Giant Cell Arteritis Therapeutic Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Giant Cell Arteritis Therapeutic Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Giant Cell Arteritis Therapeutic Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Giant Cell Arteritis Therapeutic Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Giant Cell Arteritis Therapeutic Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Giant Cell Arteritis Therapeutic Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Giant Cell Arteritis Therapeutic Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Giant Cell Arteritis Therapeutic Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Giant Cell Arteritis Therapeutic Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Giant Cell Arteritis Therapeutic Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Giant Cell Arteritis Therapeutic Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Giant Cell Arteritis Therapeutic Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Giant Cell Arteritis Therapeutic Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Giant Cell Arteritis Therapeutic Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Giant Cell Arteritis Therapeutic Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Giant Cell Arteritis Therapeutic Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Giant Cell Arteritis Therapeutic Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Giant Cell Arteritis Therapeutic Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Giant Cell Arteritis Therapeutic Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Giant Cell Arteritis Therapeutic Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Giant Cell Arteritis Therapeutic Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Giant Cell Arteritis Therapeutic Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Giant Cell Arteritis Therapeutic Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Giant Cell Arteritis Therapeutic Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Giant Cell Arteritis Therapeutic Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Giant Cell Arteritis Therapeutic Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Giant Cell Arteritis Therapeutic Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Giant Cell Arteritis Therapeutic Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Giant Cell Arteritis Therapeutic Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Giant Cell Arteritis Therapeutic Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Giant Cell Arteritis Therapeutic Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Giant Cell Arteritis Therapeutic Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Giant Cell Arteritis Therapeutic Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Giant Cell Arteritis Therapeutic Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Giant Cell Arteritis Therapeutic Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Giant Cell Arteritis Therapeutic Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Giant Cell Arteritis Therapeutic Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Giant Cell Arteritis Therapeutic Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Giant Cell Arteritis Therapeutic Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Giant Cell Arteritis Therapeutic Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Giant Cell Arteritis Therapeutic Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Giant Cell Arteritis Therapeutic Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Giant Cell Arteritis Therapeutic Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Giant Cell Arteritis Therapeutic Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Giant Cell Arteritis Therapeutic Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Giant Cell Arteritis Therapeutic Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Giant Cell Arteritis Therapeutic Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Giant Cell Arteritis Therapeutic Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Giant Cell Arteritis Therapeutic Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Giant Cell Arteritis Therapeutic Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Giant Cell Arteritis Therapeutic Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Giant Cell Arteritis Therapeutic Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Giant Cell Arteritis Therapeutic Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Giant Cell Arteritis Therapeutic Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Giant Cell Arteritis Therapeutic Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Giant Cell Arteritis Therapeutic Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Giant Cell Arteritis Therapeutic Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Giant Cell Arteritis Therapeutic Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Giant Cell Arteritis Therapeutic Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Giant Cell Arteritis Therapeutic Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Giant Cell Arteritis Therapeutic Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Giant Cell Arteritis Therapeutic Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Giant Cell Arteritis Therapeutic Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Giant Cell Arteritis Therapeutic Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Giant Cell Arteritis Therapeutic Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Giant Cell Arteritis Therapeutic Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Giant Cell Arteritis Therapeutic Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Giant Cell Arteritis Therapeutic Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Giant Cell Arteritis Therapeutic Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Giant Cell Arteritis Therapeutic Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Giant Cell Arteritis Therapeutic Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Giant Cell Arteritis Therapeutic Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Giant Cell Arteritis Therapeutic Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Giant Cell Arteritis Therapeutic Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Giant Cell Arteritis Therapeutic Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Giant Cell Arteritis Therapeutic Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Giant Cell Arteritis Therapeutic Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Abbott
  2. 8.1.1 Abbott Company Information
  3. 8.1.2 Abbott Business Overview
  4. 8.1.3 Abbott Giant Cell Arteritis Therapeutic Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Abbott Giant Cell Arteritis Therapeutic Product Portfolio
  6. 8.1.5 Abbott Recent Developments
  7. 8.2 Sanofi
  8. 8.2.1 Sanofi Company Information
  9. 8.2.2 Sanofi Business Overview
  10. 8.2.3 Sanofi Giant Cell Arteritis Therapeutic Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi Giant Cell Arteritis Therapeutic Product Portfolio
  12. 8.2.5 Sanofi Recent Developments
  13. 8.3 Johnson & Johnson Services, Inc.
  14. 8.3.1 Johnson & Johnson Services, Inc. Company Information
  15. 8.3.2 Johnson & Johnson Services, Inc. Business Overview
  16. 8.3.3 Johnson & Johnson Services, Inc. Giant Cell Arteritis Therapeutic Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Johnson & Johnson Services, Inc. Giant Cell Arteritis Therapeutic Product Portfolio
  18. 8.3.5 Johnson & Johnson Services, Inc. Recent Developments
  19. 8.4 Novartis AG
  20. 8.4.1 Novartis AG Company Information
  21. 8.4.2 Novartis AG Business Overview
  22. 8.4.3 Novartis AG Giant Cell Arteritis Therapeutic Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Novartis AG Giant Cell Arteritis Therapeutic Product Portfolio
  24. 8.4.5 Novartis AG Recent Developments
  25. 8.5 GlaxoSmithKline plc
  26. 8.5.1 GlaxoSmithKline plc Company Information
  27. 8.5.2 GlaxoSmithKline plc Business Overview
  28. 8.5.3 GlaxoSmithKline plc Giant Cell Arteritis Therapeutic Revenue and Gross Margin (2021-2026)
  29. 8.5.4 GlaxoSmithKline plc Giant Cell Arteritis Therapeutic Product Portfolio
  30. 8.5.5 GlaxoSmithKline plc Recent Developments
  31. 8.6 AbbVie, Inc.
  32. 8.6.1 AbbVie, Inc. Company Information
  33. 8.6.2 AbbVie, Inc. Business Overview
  34. 8.6.3 AbbVie, Inc. Giant Cell Arteritis Therapeutic Revenue and Gross Margin (2021-2026)
  35. 8.6.4 AbbVie, Inc. Giant Cell Arteritis Therapeutic Product Portfolio
  36. 8.6.5 AbbVie, Inc. Recent Developments
  37. 8.7 Regeneron
  38. 8.7.1 Regeneron Company Information
  39. 8.7.2 Regeneron Business Overview
  40. 8.7.3 Regeneron Giant Cell Arteritis Therapeutic Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Regeneron Giant Cell Arteritis Therapeutic Product Portfolio
  42. 8.7.5 Regeneron Recent Developments
  43. 8.8 Lahey Clinic Foundation
  44. 8.8.1 Lahey Clinic Foundation Company Information
  45. 8.8.2 Lahey Clinic Foundation Business Overview
  46. 8.8.3 Lahey Clinic Foundation Giant Cell Arteritis Therapeutic Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Lahey Clinic Foundation Giant Cell Arteritis Therapeutic Product Portfolio
  48. 8.8.5 Lahey Clinic Foundation Recent Developments
  49. 8.9 Kiniksa Pharmaceuticals, Ltd.
  50. 8.9.1 Kiniksa Pharmaceuticals, Ltd. Company Information
  51. 8.9.2 Kiniksa Pharmaceuticals, Ltd. Business Overview
  52. 8.9.3 Kiniksa Pharmaceuticals, Ltd. Giant Cell Arteritis Therapeutic Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Kiniksa Pharmaceuticals, Ltd. Giant Cell Arteritis Therapeutic Product Portfolio
  54. 8.9.5 Kiniksa Pharmaceuticals, Ltd. Recent Developments
  55. 8.10 Johns Hopkins Hospital
  56. 8.10.1 Johns Hopkins Hospital Company Information
  57. 8.10.2 Johns Hopkins Hospital Business Overview
  58. 8.10.3 Johns Hopkins Hospital Giant Cell Arteritis Therapeutic Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Johns Hopkins Hospital Giant Cell Arteritis Therapeutic Product Portfolio
  60. 8.10.5 Johns Hopkins Hospital Recent Developments
  61. 8.11 Fortis Healthcare
  62. 8.11.1 Fortis Healthcare Company Information
  63. 8.11.2 Fortis Healthcare Business Overview
  64. 8.11.3 Fortis Healthcare Giant Cell Arteritis Therapeutic Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Fortis Healthcare Giant Cell Arteritis Therapeutic Product Portfolio
  66. 8.11.5 Fortis Healthcare Recent Developments
  67. 8.12 F. Hoffmann-La Roche Ltd.
  68. 8.12.1 F. Hoffmann-La Roche Ltd. Company Information
  69. 8.12.2 F. Hoffmann-La Roche Ltd. Business Overview
  70. 8.12.3 F. Hoffmann-La Roche Ltd. Giant Cell Arteritis Therapeutic Revenue and Gross Margin (2021-2026)
  71. 8.12.4 F. Hoffmann-La Roche Ltd. Giant Cell Arteritis Therapeutic Product Portfolio
  72. 8.12.5 F. Hoffmann-La Roche Ltd. Recent Developments
  73. 8.13 Duke University Health System
  74. 8.13.1 Duke University Health System Company Information
  75. 8.13.2 Duke University Health System Business Overview
  76. 8.13.3 Duke University Health System Giant Cell Arteritis Therapeutic Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Duke University Health System Giant Cell Arteritis Therapeutic Product Portfolio
  78. 8.13.5 Duke University Health System Recent Developments
  79. 8.14 Bristol-Myers Squibb Company
  80. 8.14.1 Bristol-Myers Squibb Company Company Information
  81. 8.14.2 Bristol-Myers Squibb Company Business Overview
  82. 8.14.3 Bristol-Myers Squibb Company Giant Cell Arteritis Therapeutic Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Bristol-Myers Squibb Company Giant Cell Arteritis Therapeutic Product Portfolio
  84. 8.14.5 Bristol-Myers Squibb Company Recent Developments
  85. 8.15 American College of Rheumatology
  86. 8.15.1 American College of Rheumatology Company Information
  87. 8.15.2 American College of Rheumatology Business Overview
  88. 8.15.3 American College of Rheumatology Giant Cell Arteritis Therapeutic Revenue and Gross Margin (2021-2026)
  89. 8.15.4 American College of Rheumatology Giant Cell Arteritis Therapeutic Product Portfolio
  90. 8.15.5 American College of Rheumatology Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst